Insulinoma Clinical Trial
Official title:
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients. A single dose of 55.5-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.
68Ga-NOTA-exendin-4 is an optimal probe targeting GLP-1R. The investigators will determine the use of 68Ga-NOTA-exendin-4 PET/CT in the detection of insulinomas, and to compare its diagnostic value with conventional imaging. GLP-1R imaging, specifically expressed on pancreatic beta cell surface, might help with diagnosis of different types of nesidioblastosis (ie. focal or diffuse type), and may improve the treatment strategy of nesidioblastosis. The investigator will determine the use of 68Ga-NOTA-exendin-4 PET/CT in differentiating nesidioblastosis. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
| Withdrawn |
NCT02108782 -
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT05034783 -
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
|
Early Phase 1 | |
| Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
| Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
| Recruiting |
NCT04185350 -
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
|
Early Phase 1 | |
| Recruiting |
NCT00001276 -
Diagnosing and Treating Low Blood Sugar Levels
|
||
| Active, not recruiting |
NCT02121366 -
EUS-guided Ethanol Ablation of an Insulinoma
|
N/A | |
| Terminated |
NCT00084461 -
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00131911 -
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00005910 -
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
|
N/A | |
| Recruiting |
NCT03583528 -
DOTATOC PET/CT for Imaging NET Patients
|
||
| Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
| Recruiting |
NCT05523778 -
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
|
N/A | |
| Completed |
NCT01525082 -
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00655655 -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00075439 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A | |
| Active, not recruiting |
NCT01824875 -
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |